These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 16325969)
1. Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Rafati S; Zahedifard F; Nazgouee F Vaccine; 2006 Mar; 24(12):2169-75. PubMed ID: 16325969 [TBL] [Abstract][Full Text] [Related]
2. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Rafati S; Nakhaee A; Taheri T; Taslimi Y; Darabi H; Eravani D; Sanos S; Kaye P; Taghikhani M; Jamshidi S; Rad MA Vaccine; 2005 May; 23(28):3716-25. PubMed ID: 15882533 [TBL] [Abstract][Full Text] [Related]
3. Leishmania infantum: prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice. Rafati S; Zahedifard F; Azari MK; Taslimi Y; Taheri T Exp Parasitol; 2008 Mar; 118(3):393-401. PubMed ID: 18093586 [TBL] [Abstract][Full Text] [Related]
4. Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals. Khoshgoo N; Zahedifard F; Azizi H; Taslimi Y; Alonso MJ; Rafati S Vaccine; 2008 Oct; 26(46):5822-9. PubMed ID: 18804512 [TBL] [Abstract][Full Text] [Related]
5. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis. Iborra S; Soto M; Carrión J; Alonso C; Requena JM Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433 [TBL] [Abstract][Full Text] [Related]
6. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response. Ramos I; Alonso A; Marcen JM; Peris A; Castillo JA; Colmenares M; Larraga V Vaccine; 2008 Jan; 26(3):333-44. PubMed ID: 18093705 [TBL] [Abstract][Full Text] [Related]
7. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis. Zadeh-Vakili A; Taheri T; Taslimi Y; Doustdari F; Salmanian AH; Rafati S Vaccine; 2004 May; 22(15-16):1930-40. PubMed ID: 15121305 [TBL] [Abstract][Full Text] [Related]
8. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice. Saljoughian N; Zahedifard F; Doroud D; Doustdari F; Vasei M; Papadopoulou B; Rafati S Parasite Immunol; 2013 Dec; 35(12):397-408. PubMed ID: 23710803 [TBL] [Abstract][Full Text] [Related]
9. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice. Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis. Abdian N; Gholami E; Zahedifard F; Safaee N; Rafati S Exp Parasitol; 2011 Mar; 127(3):627-36. PubMed ID: 21187087 [TBL] [Abstract][Full Text] [Related]
11. Immunization with the cysteine proteinase Ldccys1 gene from Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits protective immune responses in a murine model of visceral leishmaniasis. Ferreira JH; Gentil LG; Dias SS; Fedeli CE; Katz S; Barbiéri CL Vaccine; 2008 Jan; 26(5):677-85. PubMed ID: 18160187 [TBL] [Abstract][Full Text] [Related]
12. Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection. Tewary P; Pandya J; Mehta J; Sukumaran B; Madhubala R FEMS Immunol Med Microbiol; 2004 Oct; 42(2):241-8. PubMed ID: 15364110 [TBL] [Abstract][Full Text] [Related]
13. Adjuvant guided polarization of the immune humoral response against a protective multicomponent antigenic protein (Q) from Leishmania infantum. A CpG + Q mix protects Balb/c mice from infection. Parody N; Soto M; Requena JM; Alonso C Parasite Immunol; 2004; 26(6-7):283-93. PubMed ID: 15541032 [TBL] [Abstract][Full Text] [Related]
14. A heterologous prime-boost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunity against experimental visceral leishmaniasis. Tewary P; Jain M; Sahani MH; Saxena S; Madhubala R J Infect Dis; 2005 Jun; 191(12):2130-7. PubMed ID: 15898000 [TBL] [Abstract][Full Text] [Related]
15. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge. Rodríguez-Cortés A; Ojeda A; López-Fuertes L; Timón M; Altet L; Solano-Gallego L; Sánchez-Robert E; Francino O; Alberola J Vaccine; 2007 Nov; 25(46):7962-71. PubMed ID: 17942199 [TBL] [Abstract][Full Text] [Related]
16. Antibiotic resistance free plasmid DNA expressing LACK protein leads towards a protective Th1 response against Leishmania infantum infection. Ramos I; Alonso A; Peris A; Marcen JM; Abengozar MA; Alcolea PJ; Castillo JA; Larraga V Vaccine; 2009 Nov; 27(48):6695-703. PubMed ID: 19747996 [TBL] [Abstract][Full Text] [Related]
17. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Melby PC; Yang J; Zhao W; Perez LE; Cheng J Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143 [TBL] [Abstract][Full Text] [Related]
18. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial. Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339 [TBL] [Abstract][Full Text] [Related]
19. Cellular vaccination with bone marrow-derived dendritic cells pulsed with a peptide of Leishmania infantum KMP-11 and CpG oligonucleotides induces protection in a murine model of visceral leishmaniasis. Agallou M; Margaroni M; Karagouni E Vaccine; 2011 Jul; 29(31):5053-64. PubMed ID: 21569815 [TBL] [Abstract][Full Text] [Related]
20. Leishmania donovani recombinant iron superoxide dismutase B1 protein in the presence of TLR-based adjuvants induces partial protection of BALB/c mice against Leishmania major infection. Daifalla NS; Bayih AG; Gedamu L Exp Parasitol; 2012 Jul; 131(3):317-24. PubMed ID: 22580023 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]